BridgeBio Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BridgeBio Pharma, Inc. (BBIO) on December 17, 2019, covering events occurring on December 12, 2019. The filing primarily addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel and compensation arrangements.
Material Changes and Governance Actions
- Board Expansion: The Board of Directors increased in size from six to seven members effective December 12, 2019.
- New Director Appointment: Jennifer E. Cook was appointed as a Class II director. Her term extends until the annual meeting following the year ending December 31, 2021.
- Director Compensation: Ms. Cook was granted an option to purchase 82,878 shares of common stock at an exercise price of $37.45 per share. These options vest in three equal annual installments over three years, contingent on continued service.
- Consulting Agreement: Ms. Cook entered into a two-year consulting agreement effective October 14, 2019, serving as a Senior Advisor on commercial activities. The agreement includes an annual fee of $200,000.
- Consulting Equity Awards: Under the consulting agreement, Ms. Cook previously received (on December 2, 2019) an option to purchase 17,084 shares at $31.14 per share and 7,152 restricted stock units (RSUs). Both awards vest 50% on the one-year anniversary and 50% on the two-year anniversary of the effective date.
Outlook, Risks, and Management Commentary
Management highlighted Ms. Cook's extensive background, including her role as CEO of GRAIL and a 25-year tenure at Roche Pharmaceuticals and Genentech, as qualifications for her board service. The filing notes that the press release announcing this appointment was issued on December 16, 2019, under Regulation FD. No specific financial risks or contingencies were disclosed in this report.
Key Facts for Investor Verification
- Verify the total number of outstanding shares and the dilution impact of the 82,878 director options and 17,084 consultant options granted to Ms. Cook.
- Confirm the vesting schedules and potential forfeiture conditions for the equity awards granted to Ms. Cook.
- Review the full text of the consulting agreement to understand the scope of services and termination provisions.
- Check subsequent filings for any changes to the Board composition or additional compensation arrangements.